Pharmaceutical companies research, develop, manufacture, and market prescription drugs and over-the-counter medicines. The industry is characterized by long development cycles (10–15 years from discovery to approval), high R&D costs, and patent-protected periods of exclusivity that generate outsized returns. GLP-1 obesity drugs from Eli Lilly and Novo Nordisk have created a once-in-a-generation growth cycle, reshaping the entire healthcare sector's investment thesis.
Track FDA PDUFA dates (approval deadlines) for late-stage pipeline drugs. Patent expiration schedules reveal revenue cliff risks. Watch Medicare drug price negotiation outcomes under the Inflation Reduction Act. Pipeline Phase 3 readouts are binary stock catalysts.